NDC 50242-078

Susvimo

Ranibizumab

Susvimo is a Intravitreal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Ranibizumab.

• Product ID: 50242-078_32b5b869-030b-4a51-ac0c-af0919ba196b
• NDC: 50242-078
• Product Type: Human Prescription Drug
• Proprietary Name: Susvimo
• Generic Name: Ranibizumab
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVITREAL
• Marketing Start Date: 2021-10-22
• Marketing Category: BLA /
• Application Number: BLA761197
• Labeler Name: Genentech, Inc.
• Substance Name: RANIBIZUMAB
• Active Ingredient Strength: 100 mg/mL
• Pharm Classes: Vascular Endothelial Growth Factor Inhibitors [MoA],Vascular Endothelial Growth Factor Inhibitor [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 50242-078-12

1 VIAL in 1 CARTON (50242-078-12) > 1 mL in 1 VIAL

• Marketing Start Date: 2021-11-29
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Susvimo" or generic name "Ranibizumab"

NDC	Brand Name	Generic Name
50242-078	Susvimo	Ranibizumab
64406-019	Byooviz	ranibizumab
50242-080	LUCENTIS	RANIBIZUMAB
50242-082	LUCENTIS	RANIBIZUMAB